FISCAL NOTE

STATE OF ALASKA 2012 LEGISLATIVE SESSION						Bill Version Fiscal Note Number () Publish Date		HB275		
Identifier (file name) HB275-DHSS-HCMS- Title Retiree Bene				IS-3-9-12 enefits: Colorectal/Drug Benefits			Med	Health and Social Services Medicaid Services Health Care Medicaid Services		
Sponsor			Lynn			Allocation		The state of the s		
		Labor and Commerce Committee			OMB Component Number 2077					
Exper	nditures/Re	venues			(Tho	usands of Dolla	ars)			
		ot include inflation ι	ınless otherwise	noted below.	1		,			
		FY13 Appropriation Requested	Included in Governor's FY13 Request	Out-Year Cost Estimates						
OPERATING EXPENDITURES		FY13	FY13	FY14	FY15	FY16	FY17	FY18		
Travel Service Comm	nal Services es odities I Outlay									
	, Benefits		85.0		85.0	85.0	85.0	85.0	85.0	
Miscel	laneous									
	TOTAL OF	PERATING	85.0	0.0	85.0	85.0	85.0	85.0	85.0	
	SOURCE		(Thousands of Dollars)							
1002	Federal Red	ceipts	42.5		42.5	42.5	42.5	42.5	42.5	
1003 1004	GF Match GF		42.5		42.5	42.5	42.5	42.5	42.5	
1004	GF/Prgm (D	GF)								
1037	GF/MH (UG									
1178	temp code (,								
	TOT	ΓAL	85.0	0.0	85.0	85.0	85.0	85.0	85.0	
POSIT	IONS									
POSITIONS Full-time										
Part-time										
Temporary										
CHANGE IN REVENUES		l								
Estimated SUPPLEMENTAL (FY12) o (discuss reasons and fund source(s) in Estimated CAPITAL (FY13) costs (discuss reasons and fund source(s) in			analysis section)			(separate supplemental appropriation required, (separate capital appropriation required,				
		e differs from prev sion of the fiscal no		f initial version	n, please no	te as such)				
Prepar	-	Kimberli Poppe-S		ommissioner				907-269-782		
Division Health Care Ser						Date/Time 3/9/12 12:00 PM				
			Assistant Commissioner				Date	3/9/2012		
		DHSS Finance &	Management Se	ervices						

(Revised 11/18/2011 OMB) Page 1 of 2

FISCAL NOTE

STATE OF ALASKA 2012 LEGISLATIVE SESSION

BILL NO.	HB275
----------	-------

Analysis

Analysis
Under this bill, certain group health insurance would have to pay for brand name drugs instead of generics up to the amount they would pay for the generics. In some cases, Medicaid would be a secondary payor. Most of the time, Medicaid could only pay up to the State Maximum Allowable Cost or Federal Upper Limit price for the generic. However, in a small number of cases, the drug would not have a State Maximum Allowable Cost or Federal Upper Limit, and Medicaid would need to pay the full difference between the brand and generic payment rate. This would increase costs to the Medicaid program.
The Department estimates that 500 claims per year would pay at the brand cost instead of the generic cost at an average increased cost of \$170 per claim, for a total increase to the budget of \$85.0. Of this, half would be Federal Receipts and half would be General Fund Match.
The bill also mandates coverage of colorectal screening for the health insurance plans. This provision would have no impact on Medicaid expenditures as it does not cover colorectal screening.

(Revised 11/18/2011 OMB) Page 2 of 2